View Older Stories
-
Scholar Rock (SRRK) PT Raised to $77 at Truist Securities
-
Scholar Rock (SRRK) PT Raised to $70 at JPMorgan
-
Scholar Rock (SRRK) PT Raised to $75; Piper Sandler: 'Buying the Dip'
-
UBS Reiterates Buy Rating on Scholar Rock (SRRK)
-
Scholar Rock (SRRK) PT Raised to $70 at H.C. Wainwright
-
Barclays Downgrades Scholar Rock (SRRK) to Equalweight
-
TD Cowen Reiterates Buy Rating on Scholar Rock (SRRK)
-
Scholar Rock (SRRK) PT Raised to $70 at Wedbush
-
Scholar Rock (SRRK) PT Raised to $76 at Truist Securities
-
Scholar Rock (SRRK) PT Raised to $72 at Raymond James
-
BMO Capital Reiterates Outperform Rating on Scholar Rock (SRRK)
-
H.C. Wainwright Reiterates Buy Rating on Scholar Rock (SRRK)
-
Scholar Rock gets FDA fast track for apitegromab in rare muscle disease
-
BMO Capital Reiterates Outperform Rating on Scholar Rock (SRRK)
-
Scholar Rock updates apitegromab regulatory status in U.S., Europe, Japan
-
H.C. Wainwright Reiterates Buy Rating on Scholar Rock (SRRK)
-
Scholar Rock Holding Corp. (SRRK) Tops Q2 EPS by 1c
-
Scholar Rock (SRRK) Reiterated at Overweight by Cantor Fitzgerald
-
Scholar Rock Holding Corp. (SRRK) Misses Q1 EPS by 3c
-
Evercore ISI Starts Scholar Rock (SRRK) at Outperform
-
Scholar Rock (SRRK) PT Raised to $57 at Jefferies
-
Scholar Rock (SRRK) PT Raised to $58 at BofA Securities
-
Scholar Rock (SRRK) PT Raised to $60 at Raymond James
-
Scholar Rock resubmits drug application to FDA for SMA treatment
-
Truist Securities on Scholar Rock (SRRK): today's Roche news 'neutral to positive'
-
BMO Capital on Scholar Rock (SRRK): emugrobart discontinuation a 'strong positive'
-
Cantor Fitzgerald: 'We now expect apitegromab to have near complete market share'
-
Scholar Rock (SRRK) PT Raised to $50 at JPMorgan
-
'We are incrementally positive on Scholar Rock (SRRK) Shares'; PT Raised at Piper Sandler
-
Scholar Rock (SRRK) PT Raised to $50 at Leerink Partners
-
Scholar Rock (SRRK) PT Raised to $53 at Barclays
-
Scholar Rock (SRRK) PT Raised to $55 at Truist Securities
-
Raymond James Reiterates Strong Buy Rating on Scholar Rock (SRRK)
-
Scholar Rock (SRRK) PT Raised to $70 at BMO Capital
-
Scholar Rock Holding Corp. (SRRK) Tops Q4 EPS by 2c
-
Scholar Rock (SRRK) PT Raised to $58 at H.C. Wainwright
-
Scholar Rock targets 2026 apitegromab BLA resubmission and launch
-
Citi Starts Scholar Rock (SRRK) at Buy
-
UBS Starts Scholar Rock (SRRK) at Buy
-
Scholar Rock's (SRRK) Apitegromab Approval Certain - Cantor Fitzgerald
-
Wolfe Research Starts Scholar Rock (SRRK) at Outperform
-
Scholar Rock (SRRK) PT Raised to $50 at BMO Capital
-
Scholar Rock Holding Corp. (SRRK) Misses Q3 EPS by 6c
-
Scholar Rock (SRRK) PT Lowered to $44 at Truist Securities
-
Truist Securities Reiterates Buy Rating on Scholar Rock (SRRK)
-
Scholar Rock stock falls after FDA flags issues at manufacturing facility
-
BofA Securities Starts Scholar Rock (SRRK) at Buy
-
Truist on Scholar Rock (SRRK): 'We See Today's Stock Weakness as a Buying Opportunity'
-
Scholar Rock (SRRK) PT Lowered to $51 at Piper Sandler
-
Scholar Rock (SRRK) PT Lowered to $44 at H.C. Wainwright


